Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents-Reference-Cited by-同舟云学术

Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents

Published:2021-06-11 Issue:3 Volume:54 Page:234-248
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Linschoten Reinier Cornelis Anthonius¹²^ORCID,Visser Elyke¹,Niehot Christa Diana³,Woude C. Janneke²,Hazelzet Jan Antonius⁴,Noord Desirée¹,West Rachel Louise¹

Affiliation:

1. Department of Gastroenterology & Hepatology Franciscus Gasthuis & Vlietland Rotterdam the Netherlands

2. Department of Gastroenterology & Hepatology Erasmus Medical Center Rotterdam the Netherlands

3. Medical Library Erasmus Medical Center Rotterdam the Netherlands

4. Department of Public Health Erasmus Medical Center Rotterdam the Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16445

Reference110 articles.

1. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

2. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

3. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial

4. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

5. Market share and costs of biologic therapies for inflammatory bowel disease in the USA

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Multi-Center Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase IIa Study to Evaluate the Efficacy, Safety and Tolerability of an Anthocyanin Rich Extract (ACRE) in Patients with Ulcerative Colitis;2024-07-21

2. White Paper: American Gastroenterological Association Position Statement: The Future of IBD Care in the United States–Removing Barriers and Embracing Opportunities;Clinical Gastroenterology and Hepatology;2024-05

3. Variation Between Hospitals in Outcomes and Costs of IBD Care: Results From the IBD Value Study;Inflammatory Bowel Diseases;2024-04-26

4. Work Productivity Impairment in Persons with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis;Journal of Crohn's and Colitis;2024-04-22

5. A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn’s Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial;Digestive Diseases and Sciences;2024-04-09